Resveratrol Inhibits Respiratory Syncytial Virus-Induced IL-6 Production, Decreases Viral Replication, and Downregulates TRIF Expression in Airway Epithelial Cells


Respiratory syncytial virus (RSV) is the most common pathogen responsible for lower respiratory diseases in children. So far, there is no effective treatment or preventative vaccine available for RSV infection, although ribavirin and dexamethasone are commonly prescribed. Resveratrol has been shown to inhibit the replication of several other viruses, thus the effect of resveratrol on RSV-induced inflammatory mediators in 9HTEo cell cultures was evaluated, and possible mechanisms of action were explored and compared with dexamethasone and ribavirin. Incubation with resveratrol resulted in decreased IL-6 production and partial inhibition of RSV replication. Resveratrol treatment also inhibited virus-induced TIR-domain-containing adapter-inducing interferon-β (TRIF) and TANK binding kinase 1 (TBK1) protein expression. These data demonstrate the ability of resveratrol to inhibit cytokine production by RSV in airway epithelial cells, indicating that it might be a therapeutic agent with both anti-inflammatory and antiviral potential for the treatment of RSV infection.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6


  1. 1.

    Jiang, Z., M. Kunimoto, and J.A. Patel. 1998. Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. Journal of Virology 72(3): 2496–2499.

    PubMed  CAS  Google Scholar 

  2. 2.

    Mastronarde, J.G., M.M. Monick, T.J. Gross, and G.W. Hunninghake. 1996. Amiloride inhibits cytokine production in epithelium infected with respiratory syncytial virus. American Journal of Physiology (2 Pt 1):L201–L207.

    Google Scholar 

  3. 3.

    Roosevelt, G., K. Sheehan, J. Grupp-Phelan, R.R. Tanz, and R. Listernick. 1996. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 348(9023): 292–295.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Buckingham, S.C., H.S. Jafri, and A.J. Bush. 2002. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. Journal of Infectious Diseases 185(9): 1222–1228.

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    van Woensel, J.B., W.M. van Aalderen, W. de Weerd, N.J. Jansen, J.P. van Gestel, D.G. Markhorst, et al. 2003. Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus. Thorax 58(5): 383–387.

    PubMed  Article  Google Scholar 

  6. 6.

    Guerguerian, A.M., M. Gauthier, M.H. Lebel, C.A. Farrell, and J. Lacroix. 1999. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medice 160(3): 829–834.

    CAS  Google Scholar 

  7. 7.

    Docherty, J.J., M.M. Fu, B.S. Stiffler, R.J. Limperos, C.M. Pokabla, and A.L. DeLucia. 1999. Resveratrol inhibition of herpes simplex virus replication. Antiviral Research 43(3): 145–155.

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Palamara, A.T., L. Nencioni, K. Aquilano, G. De Chiara, L. Hernandez, F. Cozzolino, et al. 2005. Inhibition of influenza A virus replication by resveratrol. Journal of Infectious Diseases 191(10): 1719–1729.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Evers, D.L., X. Wang, S.M. Huong, D.Y. Huang, and E.S. Huang. 2004. 3,4′,5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Research 63(2): 85–95.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Docherty, J.J., T.J. Sweet, E. Bailey, S.A. Faith, and T. Booth. 2006. Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Research 72(3): 171–177.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Youn, H.S., J.Y. Lee, K.A. Fitzgerald, H.A. Young, S. Akira, and D.H. Hwang. 2005. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. Journal of Immunology 175(5): 3339–3346.

    CAS  Google Scholar 

  12. 12.

    Groskreutz, D.J., M.M. Monick, L.S. Powers, T.O. Yarovinsky, D.C. Look, and G.W. Hunninghake. 2006. Respiratory syncytial virus inducesTLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. Journal of Immunology 176(3): 1733–1740.

    CAS  Google Scholar 

  13. 13.

    Rudd, B.D., J.J. Smit, R.A. Flavell, L. Alexopoulou, M.A. Schaller, A. Gruber, et al. 2006. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. Journal of Immunology 176(3): 1937–1942.

    CAS  Google Scholar 

  14. 14.

    Majde, J.A. 2000. Viral double-stranded RNA, cytokines, and the flu. Journal of Interferon and Cytokine Research 20(3): 259–272.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Xie, X.H., H.K. Law, L.J. Wang, X. Li, X.Q. Yang, and E.M. Liu. 2009. Lipopolysaccharide induces IL-6 production in respiratory syncytial virus-infected airway epithelial cells through the toll-like receptor 4 signaling pathway. Pediatric Research 65(2): 156–162.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Donnelly, L.E., R. Newton, G.E. Kennedy, P.S. Fenwick, R.H. Leung, K. Ito, et al. 2004. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. American Journal of Physiology. Lung Cellular and Molecular Physiology 287(4): 774–783.

    Article  Google Scholar 

  17. 17.

    Ciencewicki, J., L. Brighton, W.D. Wu, M. Madden, and I. Jaspers. 2006. Diesel exhaust enhances virus- and poly(I:C)-induced Toll-like receptor 3 expression and signaling in respiratory epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 290(6): L1154–L1163.

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Melkamu, T., D. Squillace, H. Kita, and S.M. O'Grady. 2009. Regulation of TLR2 expression and function in human airway epithelial cells. Journal of Membrane Biology 229(2): 101–113.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Guillot, L., R. Le Goffic, S. Bloch, N. Escriou, S. Akira, M. Chignard, et al. 2005. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. Journal of Biological Chemistry 280(7): 5571–5580.

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Le Goffic, R., V. Balloy, M. Lagranderie, L. Alexopoulou, N. Escriou, R. Flavell, et al. 2006. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathogens 2(6): e53.

    PubMed  Article  Google Scholar 

  21. 21.

    Libermann, T.A., and D. Baltimore. 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Molecular and Cellular Biology 10(5): 2327–2334.

    PubMed  CAS  Google Scholar 

  22. 22.

    Li, Z.W., R.C. Rickert, and M. Karin. 2004. Genetic dissection of antigen receptor induced-NF-kappaB activation. Molecular Immunology 41(6–7): 701–714.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, et al. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633): 640–643.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Cusson-Hermance, N., S. Khurana, T.H. Lee, K.A. Fitzgerald, and M.A. Kelliher. 2005. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. Journal of Biological Chemistry 280(44): 36560–36566.

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Tojima, Y., A. Fujimoto, M. Delhase, et al. 2000. NAK is an IkappaB kinase-activating kinase. Nature 404(6779): 778–782.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    An, H., W. Zhao, J. Hou, Y. Zhang, Y. Xie, Y. Zheng, et al. 2006. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 25(6): 919–928.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Levine, S.J., P. Larivée, C. Logun, C.W. Angus, and J.H. Shelhamer. 1993. Corticosteroids differentially regulate secretion of IL-6, IL-8, and G-CSF by a human bronchial epithelial cell line. American Journal of Physiology 265(4 Pt1): L360–L368.

    PubMed  CAS  Google Scholar 

  28. 28.

    De Franceschi, L., G. Fattovich, F. Turrini, K. Ayi, C. Brugnara, F. Manzato, et al. 2000. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31(4): 997–1004.

    PubMed  Article  Google Scholar 

  29. 29.

    Zang, N., X. Xie, Y. Deng, S. Wu, L. Wang, C. Peng, et al. 2011. Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice. Journal of Virology 85(24): 13061–13068.

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Leonard, S.S., C. Xia, B.H. Jiang, B. Stinefelt, H. Klandorf, and G.K. Harris. 2003. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochemical and Biophysical Research Communications 309(4): 1017–1026.

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Baur, J.A., and D.A. Sinclair. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews. Drug Discovery 5(6): 493–506.

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Lu, C., I.F. Bambang, J.S. Armstrong, and M. Whiteman. 2008. Resveratrol blocks high glucose-induced mitochondrial reactive oxygen species production in bovine aortic endothelial cells: role of phase 2 enzyme induction? Diabetes, Obesity & Metabolism 10(4): 347–349.

    Article  CAS  Google Scholar 

  33. 33.

    Liu, T., S. Castro, A.R. Brasier, M. Jamaluddin, R.P. Garofalo, and A. Casola. 2004. Reactive oxygen species mediate virus-induced STAT activation: role of tyrosine phosphatases. Journal of Biological Chemistry 279(4): 2461–2469.

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Castro, S.M., A. Guerrero-Plata, G. Suarez-Real, P.A. Adegboyega, G.N. Colasurdo, and A.M. Khan. 2006. Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation. American Journal of Respiratory and Critical Care Medicine 174(12): 1361–1369.

    PubMed  Article  CAS  Google Scholar 

Download references


This study was supported by the Program for New Century Excellent Talents in University (06-775), the Key program of Chongqing Medical University, and Specialized Research Fund for the Doctoral Program of Higher Education of China (Grant No. 20105503120003)

Author information



Corresponding author

Correspondence to En-mei Liu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Xie, X., Zang, N., Li, S. et al. Resveratrol Inhibits Respiratory Syncytial Virus-Induced IL-6 Production, Decreases Viral Replication, and Downregulates TRIF Expression in Airway Epithelial Cells. Inflammation 35, 1392–1401 (2012).

Download citation


  • resveratrol
  • respiratory syncytial virus
  • toll-like receptor
  • inflammation
  • airway epithelial cell